Emergent BioSolutions Inc. EBS

What this company does

Emergent BioSolutions provides a product portfolio, a product development portfolio, and contract development and manufacturing services addressing accidental, deliberate and naturally occurring public health threats. As of December 31, 2025, it had a portfolio of 11 products focused on addressing global public health threats such as smallpox, mpox, anthrax, Ebola and opioid overdose emergencies. As of December 31, 2025, it had approximately 900 employees globally. The company has four development and manufacturing sites in the U.S. and Canada, with its Winnipeg and Gaithersburg sites housing development services, its Canton, Lansing and Winnipeg sites housing commercial drug substance production, and its Winnipeg site housing drug product and packaging operations. Emergent BioSolutions is organized into three operating segments: a Commercial Product Segment consisting of NARCAN Nasal Spray and KLOXXADO Spray, an MCM Products Segment consisting of Anthrax and Smallpox medical countermeasure products and other products, and a Services Segment consisting of its Bioservices portfolio. Its Government-MCM business focuses primarily on the procurement of MCM products and procured product candidates by domestic and international government customers, with an emphasis on the USG, which is its largest customer.

Written from the business description in Emergent BioSolutions Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.